FLORHAM PARK, N.J. — October 7, 2025 — Leads & Copy — Cellectar Biosciences, Inc. (NASDAQ:CLRB) has announced an agreement with institutional investors to exercise existing warrants, expecting gross proceeds of approximately $5.8 million. The funds will support working capital, a Phase 1b clinical study for CLR 121125 in triple-negative breast cancer, and preparation for a Conditional Marketing Authorization (CMA) filing with the European Medicines Agency.
The warrants, issued on October 25, 2022, July 21, 2024, and July 2, 2025, involved the exercise of 1,048,094 existing warrants. Exercising holders will receive new Series I and Series II warrants, immediately exercisable at $6.00 per share, with terms of five years and 18 months, respectively.
Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the transaction. Cellectar Biosciences is focused on developing cancer treatments using its Phospholipid Drug Conjugate™ (PDC) delivery platform. Its pipeline includes iopofosine I 131 and CLR 121225, targeting various cancers.
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
Source: Cellectar Biosciences, Inc.
